Development status: Approved, off-patent, discontinued in most countries

Gram-positive activity

Mechanism of Action/Target pathogen: Binds to the bacterial 50S ribosomal subunit and inhibits the elongation process of protein synthesis

Additional information: Component of the combination product quinupristin/dalfopristin